Alteogen Inc. said that it has entered into an exclusive license agreement with Daiichi Sankyo (DSKYF.PK). As per the terms of the ...

A subcutaneous version of Daiichi Sankyo’s AstraZeneca-partnered blockbuster antibody-drug conjugate (ADC) Enhertu could be ...

Daiichi Sankyo has been granted breakthrough status by the FDA for patritumab deruxtecan, a HER3-targeted antibody-drug conjugate (ADC) in clinical trials for lung cancer. The designation ...

Daiichi Sankyo Co. will seek to maintain its edge over competitors in precision cancer therapies, by pushing ahead with clinical trials of drug candidates being developed using new technology ...

DS was established from the merger of Daiichi Pharmaceutical and Sankyo in 2005. As of 2021, we estimate over 60% of DS’ revenue comes from lucrative business lines, such as pain medication ...

As one of the leading Japanese pharmaceutical companies with headquarters in Europe, Daiichi Sankyo aims to revolutionize treatment standards. Daiichi Sankyo, a pharmaceutical group boasting over ...

Japan's Daiichi Sankyo has claimed its first worldwide approval ... 2 trial which revealed a 48% overall response rate with the drug in previously-treated ATL patients. ATL is a rare and highly ...

The drug, developed with Japan's Daiichi Sankyo, showed an improvement in progression-free survival and overall survival in certain cancer patients regardless of their hormone receptor status.

Hiroyuki Okuzawa, President and COO at Daiichi Sankyo, says the company is working ... to expand production of the so-called antibody drug conjugates (ADCs). He speaks with Shery Ahn on "Bloomberg ...

Bernstein analyst Miki Sogi assigned a Buy rating to Daiichi Sankyo Company (DSKYF – Research Report) today and set a price target of ...

The campaign is presented by Daiichi-Sankyo and AstraZeneca ... In addition to informing viewers about the drug itself, Dan Switzer, head of Daiichi’s U.S. oncology business, recently told ...